5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.
Treatment of daunorubicin with methanolic ammonia affords 5-iminodaunorubicin, the first quinone-modified analogue of either daunorubicin or adriamycin. This product retains antileukemic activity in mice, is less cardiotoxic by electrocardiographic measurements in rats, and is nonmutagenic in Salmonella typhimurium (Ames test).
D000818:Animals; D004247:DNA / Q000378:metabolism; D004273:DNA, Neoplasm / Q000096:biosynthesis; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000627:therapeutic use / Q000633:toxicity; D006331:Heart Diseases / Q000139:chemically induced*; D007939:Leukemia L1210 / Q000378:metabolism; D051379:Mice; D009153:Mutagens; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D012334:RNA, Neoplasm / Q000096:biosynthesis; D051381:Rats
D004273:DNA, Neoplasm; D009153:Mutagens; D012334:RNA, Neoplasm; D004247:DNA; C018979:5-iminodaunorubicin; D003630:Daunorubicin